Ovid Therapeutics Inc (OVID)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $479.38M
Last updated: Nov 17, 2026 at 4:33 PM ET
Ovid Therapeutics Inc (OVID) Statistics
Ovid Therapeutics (OVID) has a market cap of $479.38M and an enterprise value of $465.57M. It kept -2971.33% of revenue as net income over the last 12 months. Its share count is up 185.48% from a year earlier.
Total Valuation
Enterprise value is 2.88% below the market cap, as cash exceeds debt.
| Market Cap | $479.38M |
|---|---|
| Enterprise Value | $465.57M |
| Latest price (Nov 17, 2026) | $2.22 |
Key Dates
The next earnings report is expected on Mar 16, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Mar 16, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 10, 2026 |
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 310.6x and 2.3x. Its year-end P/S ranged from 11.2x to 580.0x from 2020 to 2025.
| P/S Ratio | 310.6x |
|---|---|
| Forward P/S | 591.5x |
| P/B Ratio | 2.3x |
| P/TBV Ratio | 2.9x |
Price Statistics
The stock is up 70.11% over 52 weeks and trades 10.84% below its 50-day average.
| Beta (1Y) | 1.46 |
|---|---|
| 52-Week Change | +70.11% |
| 1-Month Change | +2.30% |
| 3-Month Change | -24.23% |
| 6-Month Change | -7.50% |
| 5-Year Change | -25.29% |
| Total Return (1Y) | +70.11% |
| Total Return (3Y CAGR) | -12.11% |
| Total Return (5Y CAGR) | -8.01% |
| Return vs SPY (1Y) | +56.62% |
| Max Drawdown (1Y) | -27.36% |
| Max Drawdown (3Y) | -93.69% |
| Sharpe Ratio (1Y) | 0.68 |
| Correlation with SPY (1Y) | 0.26 |
| 50-Day Average | $2.49 |
| 200-Day Average | $2.42 |
| 52-Week Range | $1.21 to $3.10 |
| RSI (14 Days) | 40.1 |
| Average Volume (20 Days) | 2.63M |
The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 11.97x current liabilities, and total debt is 0.00x shareholder equity.
| Current Ratio | 11.97x |
|---|---|
| Quick Ratio | 11.97x |
| Debt / Equity | 0.00x |
Returns and Efficiency
Return on equity is -21.70% over the last 12 months, against a 5-year average of -16.86%.
| Return on Equity (ROE) | -21.70% |
|---|---|
| Return on Assets (ROA) | -19.40% |
| Return on Capital Employed (ROCE) | -20.49% |
| ROE (5Y Average) | -16.86% |
| ROA (5Y Average) | -9.66% |
| ROIC (5Y Average) | -10.53% |
| Asset Turnover | 0.01x |
Scores
OVID has an Altman Z-Score of 9.18, in the safe zone above 2.99, and a Piotroski F-Score of 3 of 9, in the average band of 3 to 7.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | 9.18 |
|---|---|
| Altman Z Zone | Safe |
| Piotroski F-Score | 3 of 9 |
| Piotroski Strength | Average |
Income Statement
Revenue of $1.45M over the last 12 months is down 78.05% from the 12 months before.
| Revenue | $1.45M |
|---|---|
| Revenue Growth (YoY) | -78.05% |
| Gross Profit | $1.45M |
| Operating Income | -$68.20M |
| Pretax Income | -$43.11M |
| Net Income | -$43.11M |
| EBITDA | -$41.77M |
| EBIT | -$43.11M |
| Reported EPS (TTM) | -$0.24 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 89.39% of the $222.24M in total assets.
| Cash and Equivalents | $13.81M |
|---|---|
| Total Debt | $0 |
| Net Cash | $13.81M |
| Net Cash Per Share | $0.07 |
| Working Capital | $130.10M |
| Shareholder Equity | $198.67M |
| Book Value Per Share | $0.98 |
| Tangible Book Value | $155.98M |
| Tangible Book Per Share | $0.77 |
| Total Assets | $222.24M |
| Total Liabilities | $23.57M |
Balance sheet as of Sep 30, 2026.
Cash Flow
| Operating Cash Flow | -$57.78M |
|---|---|
| FCF Per Share | -$0.30 |
| Depreciation and Amortization | $1.34M |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is -4700.28%.
| Gross Margin | 100.00% |
|---|---|
| Operating Margin | -4700.28% |
| Pretax Margin | -2971.33% |
| Net Margin | -2971.33% |
| EBITDA Margin | -2878.77% |
| EBIT Margin | -2971.26% |
Growth
Revenue grew 68.99% a year over 3 years.
| Revenue Growth (3Y CAGR) | +68.99% |
|---|---|
| Revenue Growth (5Y CAGR) | -10.48% |
| Book Value Per Share Growth (2Y CAGR) | +13.49% |
| Tangible Book Per Share Growth (2Y CAGR) | -6.49% |
Dividends and Yields
OVID does not pay a dividend.
| Buyback Yield | -14.79% |
|---|---|
| Shareholder Yield | -14.79% |
Peer Position
Against 4 similar companies, OVID has the highest P/S.
P/S RatioPeer median 27.9x
Revenue Growth (Trailing 4 Quarters, YoY)Peer median -83.94%
| P/S Ratio | 310.6x vs 27.9x median |
|---|---|
| Revenue Growth (Trailing 4 Quarters, YoY) | -78.05% vs -83.94% median |
Analyst Forecast
Consensus estimates put revenue growth at -81.12% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | -81.12% |
|---|
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About OVID
What is OVID's market cap?
Ovid Therapeutics has a market cap of $479.38M. Its enterprise value, which adds debt and subtracts cash, is $465.57M.
How many shares of OVID are outstanding?
Ovid Therapeutics has 203.02M shares outstanding. The count is up 185.48% from a year earlier.
Does OVID pay a dividend?
No. Ovid Therapeutics does not pay a dividend.
How much debt does OVID have?
Ovid Therapeutics has $0 of total debt and $13.81M of cash and equivalents, a net cash position of $13.81M.
OVID pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors